EU’s CHMP Recommends Approval of Tegsedi (Inotersen) for Treatment of FAP
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tegsedi (inotersen) as a treatment for Stage 1 or 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR), also known as familial amyloid polyneuropathy (FAP). The announcement comes from Akcea Therapeutics and…